Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Sex differences and outcomes after transcatheter aortic valve implantation in severe aortic stenosis – an analysis of 488 cases
Session:
Comunicações Orais - Sessão 05 - Doença cardiovascular na mulher
Speaker:
Diogo Santos Ferreira
Congress:
CPC 2023
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.2 Cardiovascular Disease in Women
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Diogo Santos Ferreira; Silvia Diaz; Cláudio Guerreiro; Gualter Silva; Mariana Silva; Mariana Brandão; Fábio Nunes; Rafael Teixeira; Eulália Pereira; Gustavo Pires-Morais; Bruno Melica; Lino Santos; Alberto Rodrigues; Pedro Braga; Ricardo Fontes-Carvalho
Abstract
<p>BACKGROUND: Conflicting results have been reported regarding survival after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (SAS) treatment in women, when compared to men.</p> <p>PURPOSE: Compare mortality after TAVI for SAS, according to sex.</p> <p>METHODS: A single-centre retrospective database of all TAVI performed between 2011 and 2019 was analyzed, and clinical, echocardiographic and blood-analysis data were compared according to sex. Primary endpoint was defined as time to all-cause death of last follow-up over the five years after intervention. Secondary endpoint was defined as a reduction of at least one New York Heart Association (NYHA) class after TAVI. Kaplan-Meier curves, log-rank test, Cox proportional hazard model adjusted for EuroSCORE II, as well as Pearson’s Chi-squared test, Wilcoxon rank sum test and Fisher’s exact test were used, as appropriate. <em>p</em><0.05 was considered statistically significant.</p> <p>RESULTS: From a total of 488 TAVI, 252 (51.6%) women were treated. They were older (84 <em>vs.</em> 80 years-old, p<0.001), had a lower body surface area, and had a higher estimated surgical risk, using EuroSCORE II (4.5 <em>vs.</em> 3.8, p=0.011) and STS-mortality (4.46 <em>vs.</em> 3.44, p<0.001). There was also a lower prevalence of diabetes <em>mellitus</em>, coronary artery disease and peripheral artery disease, lower estimated creatinine clearance, as well as a lower frequency of previous pacemaker implantation. Women had a lower functional aortic valve area, higher transvalvular gradients and ejection fraction. TAVI design was no different according to sex, but smaller valves were implanted in women. In the whole cohort, there was a 40% mortality over 5 years after treatment. No statistically significant differences were found regarding survival after TAVI in both univariate and multivariate analysis, after adjusting for EuroSCORE II. The latter had a statistically significant association with the primary endpoint [hazard ratio 1.03 (1.01-1.05), p=0.004). Despite similar NYHA class before intervention, there was a lower frequency of NYHA class improvement in women after TAVI (61% <em>vs.</em> 72%, p=0.034).</p> <p>CONCLUSIONS: Despite exhibiting a higher estimated surgical risk, mortality after TAVI was not found to be different in women. However, heart failure symptomatic improvement was less frequent in this subset.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site